PHA-543613 – Kodiac biolabs

Our opinion on this compoundNiche research probe

52/100

Premier selective alpha-7 full agonist tool compound with strong bench utility but no human data and a class history of clinical failure

Look, the alpha-7 nicotinic field has one of the longer lists of clinical disappointments in CNS pharmacology. GTS-21 stalled in development. Encenicline failed Phase 2 trials in both schizophrenia and Alzheimer disease and Pfizer shelved it. The promise of selective nicotinic receptor pharmacology in cognitive disease has been held out for thirty years without a clean win in humans. So why is PHA-543613 worth discussing? Because it isn’t a clinical candidate. It’s a tool, and on that specific dimension it’s the best one available.

The distinguishing feature is full agonism paired with genuine subtype selectivity. Most alpha-7 compounds in active research use are partial agonists: tropisetron sits at roughly 25 to 40 percent intrinsic activity at alpha-7, GTS-21 at 30 to 50 percent, encenicline at 60 to 70 percent. PHA-543613 comes in at 80 to 90 percent of the acetylcholine maximum across Xenopus oocyte and heterologous cell-line expression systems. That matters when the research question is what happens under near-maximal alpha-7 engagement. Partial agonists contaminate the readout at the ceiling. The roughly 100-fold selectivity window over alpha-4-beta-2 and alpha-3-beta-4 subtypes means youre not running an inadvertent parallel experiment on the rest of the nAChR family whenever you attribute an effect to alpha-7.

The recent preclinical record is substantive and methodologically credible. Hijazi et al. (2023) used the presenilin 1 and presenilin 2 conditional double-knockout mouse, which is among the more mechanistically faithful familial AD models in current use, and showed meaningful cognitive rescue with PHA-543613. The combination pharmacology work is what we find most interesting: aged-rat studies pairing PHA-543613 with memantine at doses that extrapolate plausibly to clinically available memantine exposures demonstrate synergy that neither compound produces as monotherapy. The biological rationale is coherent: alpha-7-mediated calcium influx and downstream PI3K/Akt signaling running in parallel with NMDA receptor antagonism targeting a distinct synaptic calcium-handling mechanism. Thats a genuinely testable combination hypothesis with real translational scaffolding.

We don’t love the translational picture, honestly. No human data, not Phase 1, not even formal IND-enabling studies on record. The rodent cognitive models anchoring PHA-543613’s preclinical case, scopolamine-induced impairment, MK-801 blockade, amyloid fragment infusion, are the same models that predicted clinical success for encenicline and several other alpha-7 compounds. Those predictions did not hold. That track record has to weigh on how much you trust bench-to-clinic extrapolation in this receptor class specifically.

What pushes the bench value score up is exactly what you’d expect from a well-characterized tool compound. If youre doing alpha-7 nAChR receptor biology, combination cholinergic pharmacology, or AD mechanistic work in rodent models, this compound is difficult to replace. No other widely available molecule gives you selective full agonism with a brain-to-plasma ratio of five to ten in rodents, confirmed oral bioavailability, and two decades of published dose-response literature to anchor new studies against. For investigators running AD combination pharmacology programs or neurotransmitter systems research, PHA-543613 earns a serious toolkit position. For anyone looking for a clinical development candidate in the alpha-7 class, bradanicline and the newer quinuclidine-benzofuran series are the more plausible targets.

Novelty: 42
Mechanism promise: 58
In-category differentiation: 72
Evidence quality: 40
Translational signal: 30
Research bench value: 74

Rationale PHA-543613 scores highest on differentiation and bench value: it is the definitive selective alpha-7 nAChR full agonist tool compound, essentially irreplaceable for investigators who need saturating, selective alpha-7 engagement uncomplicated by partial-agonist ceiling effects or nAChR subtype bleed-through. Translational signal is low given zero human trials and the alpha-7 class’s string of clinical failures; mechanism is solid but not novel by current standards. Overall 52 reflects an indispensable probe for a specific, relatively narrow research niche.

Selective alpha-7 nicotinic acetylcholine receptor full agonist (preclinical research compound)

A quinuclidine furo[2,3-c]pyridine-5-carboxamide developed at Pfizer in the mid-2000s as a brain-penetrant, orally bioavailable selective alpha-7 nicotinic full agonist with substantial preclinical pharmacology in rodent cognitive models. The principal high-potency selective alpha-7 nicotinic agonist in current research use as a tool compound, with no advancement to human clinical trials but extensive use in fundamental and combination-pharmacology studies including the recent presenilin double-knockout mouse model of Alzheimer disease and synergistic combination work with memantine in aged rats.

Abstract

PHA-543613 is a small-molecule, brain-penetrant, orally bioavailable selective full agonist of the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor, originated at Pfizer Global Research and Development in the mid-2000s as part of an alpha-7 nicotinic receptor medicinal-chemistry program for cognitive enhancement applications. The compound is a quinuclidine furo[2,3-c]pyridine-5-carboxamide, structurally related to the quinuclidine-amide alpha-7 family that includes encenicline (a quinuclidine benzothiophene-2-carboxamide) and bradanicline (a quinuclidine benzofuran-2-carboxamide), distinguished by the fused furo[2,3-c]pyridine bicyclic system in the amide-bearing aryl group. The chemistry was disclosed in the seminal Wishka et al. (2006) Journal of Medicinal Chemistry report from Pfizer, which described the structure-activity relationship study, the optimization to PHA-543613 as the lead compound, and the preliminary pharmacology supporting brain penetration, oral bioavailability, and alpha-7 selectivity [1]. The compound has not been advanced to human clinical trials; the published pharmacology is principally preclinical (rodent species). PHA-543613 binds the human alpha-7 nicotinic receptor at the orthosteric (acetylcholine) site with low-nanomolar affinity (Ki approximately 8 nanomolar at human alpha-7 expressed in heterologous systems) and acts as a full agonist with intrinsic functional activity of approximately 80 to 90 percent of the acetylcholine maximum response in Xenopus oocyte and cell-line expression systems, comparable to bradanicline and substantially higher than encenicline (60 to 70 percent), tropisetron (25 to 40 percent), and GTS-21 (30 to 50 percent). Selectivity over other neuronal nicotinic subtypes (alpha-4-beta-2, alpha-3-beta-4) is approximately 100-fold or greater. The compound exhibits good oral bioavailability and high brain penetration in rodent species (brain-to-plasma ratio approximately 5 to 10), supporting central nervous system pharmacology at oral doses of 0.3 to 10 milligrams per kilogram. The principal published pharmacology comprises rodent behavioral studies in scopolamine-induced cognitive impairment, MK-801-induced cognitive impairment, beta-amyloid-induced cognitive deficit (the Aβ25-35 mouse model), aged-rat working memory paradigms, and the recent Hijazi et al. (2023) presenilin 1 and presenilin 2 conditional double knockout mouse model of familial Alzheimer disease [2, 3, 4]. The compound has demonstrated reversal of cognitive deficits across these models with effect sizes substantially exceeding the alpha-7 partial agonists tested in parallel comparisons (notably exceeding galantamine in head-to-head comparisons in the aged-rat model). Substantial recent work has characterized the synergistic combination of PHA-543613 with memantine (an NMDA receptor antagonist, the FDA-approved Alzheimer disease drug) in aged rats, with the combination demonstrating greater cognitive benefit than either compound as monotherapy at clinically translatable doses [4]. The combination work supports a contemporary research-clinical hypothesis that combination pharmacology of alpha-7 nicotinic full agonism (PHA-543613-class) with NMDA receptor antagonism (memantine) and acetylcholinesterase inhibition (donepezil-class) may produce cognitive benefits exceeding those achievable with monotherapy in any single mechanism class. PHA-543613 has not been licensed to a clinical-development entity for human trials as of the most recent monograph revision; the compound therefore serves as a research tool rather than as a clinical candidate. Research-grade PHA-543613 is widely available from chemical suppliers at moderate cost and is one of the most extensively used alpha-7 nicotinic receptor agonist tool compounds in contemporary fundamental pharmacology research. This monograph reviews the chemistry, synthesis, and stereochemistry of PHA-543613; the receptor pharmacology in molecular and electrophysiological detail; the preclinical pharmacokinetic record in rodent species; the comprehensive preclinical pharmacology across cognitive enhancement, neuroprotection, and combination pharmacology applications; sourcing, reconstitution, and stack-interaction considerations; the safety record (preclinical only); and a structured comparative assessment of five alpha-7 nicotinic acetylcholine receptor candidates against PHA-543613 on the five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1356Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.